Further research on therapeutic combinations of inhibitors targeting downstream signals of BCR-ABL along with BCR-ABL inhibitors will be an important therapeutic strategy for CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.